Highlights InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 14/05/2024 pm IST			5-day change	1st Jan Change
5.13 ^HKD	-0.58%		+0.98%	-25.54%

09:15am	Innocare Pharma Posts Q1 Loss	MT
13/05	InnoCare Logs Loss in Q1	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innocare Pharma Posts Q1 Loss	12:45pm	MT
InnoCare Logs Loss in Q1	13/05	MT
InnoCare Pharma Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	29/03	CI
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China	13/03	CI
InnoCare to Shrink Loss in 2023	29/01	MT
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023	29/01	CI
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China	24/01	CI
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program	22/01	CI
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA	16/01	CI
InnoCare Pharma Appoints Xin Fu as Chief Financial Officer	18/12	CI
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332	17/12	CI
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH	11/12	CI
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	13/11	CI
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China	27/23/27	CI
InnoCare Pharma Limited commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.	20/23/20	CI
InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib	14/23/14	CI
InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology	13/23/13	CI
InnoCare Pharma Launches HK$200 Million Share Buyback Plan	08/23/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Highlights

Filters